Sanofi

We chase the miracles of science so you can chase your dreams.

People Stories

We’re proud to spotlight those who inspire us to keep going further in the work we do.

A woman wearing a black wetsuit holds a surfboard under blue skies and sunshine while looking out to the horizon with a hopeful and determined expression.​

Céline, living with secondary progressive multiple sclerosis

France

Two women in black wetsuits standing on a beach with a surfboard, ready for surfing

The Power of Chasing A Dream

Every day, we chase the miracles of science to improve people’s lives. We apply our deep understanding of the immune system to develop breakthrough innovations in medicines and vaccines so you can focus on what matters most, chasing your dreams. If you’re chasing your dreams, remember... you’re not alone. We’re right beside you. 


Our Latest Articles

3D rendering of a purple and gray influenza virus particle on a gradient purple background

Your Health

November 3, 2025

Flunomics: Assessing the True Impact of Flu

About Us

Who We Are

We are an R&D driven,
AI-powered biopharma company committed to improving people’s lives and creating compelling growth.

Our Pipeline

5

Therapeutic areas

93

Compounds in clinical development

26

Clinical trials in phase 3

Pursue Progress. Discover Extraordinary. 

Better is out there. Better medications, better outcomes, better science. It's all down to people like you, from different backgrounds, in different locations, doing different roles. Take the most important step in your career: help us change the lives of people, families and communities for the better.

Our Latest Press Releases


October 28, 2025
Press release: Sanofi successfully prices USD 3 billion of bond issue

October 24, 2025
Press release: Q3: continued sales and earnings progress

October 22, 2025
Press Release: Sanofi’s efdoralprin alfa met all primary and key secondary endpoints in alpha-1 antitrypsin deficiency emphysema phase 2 study

October 20, 2025
Press Release: Sanofi’s Tzield accepted for expedited review in the US for stage 3 type 1 diabetes through FDA Commissioner's National Priority Voucher pilot program